⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for rituximab

Every month we try and update this database with for rituximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell LymphomaNCT05575973
Diffuse Large B...
Mitoxantrone Hy...
Rituximab
Lenalidomide
60 Years - 75 YearsHuazhong University of Science and Technology
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaNCT00005959
Lymphoma
filgrastim
rituximab
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
18 Years - National Cancer Institute (NCI)
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)NCT00450385
Lymphoma
Rituximab
Cyclophosphamid...
Doxorubicin
Prednisone
Vincristine
18 Years - 120 YearsUniversity of Miami
Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaNCT00736450
Contiguous Stag...
Noncontiguous S...
Stage I Adult D...
Stage III Adult...
Stage IV Adult ...
oblimersen sodi...
rituximab
cyclophosphamid...
doxorubicin hyd...
vincristine sul...
prednisone
biopsy
microarray anal...
immunohistochem...
gene expression...
cytogenetic ana...
19 Years - University of Nebraska
Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's LymphomaNCT00055640
Lymphoma
rituximab
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
microarray anal...
18 Years - Case Comprehensive Cancer Center
Aza-SAHA-GBM With AutoSCT for Refractory LymphomaNCT01983969
Advanced Cancer...
Lymphoma
Azacitidine
Vorinostat
Gemcitabine
Busulfan
Melphalan
Dexamethasone
Caphosol
Glutamine
Pyridoxine
Rituximab
15 Years - 65 YearsM.D. Anderson Cancer Center
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System LymphomaNCT00335140
Lymphoma
Rituximab
Cytarabine
Dexamethasone
Leucovorin
Methotrexate
Procarbazine
Vincristine
18 Years - Eastern Cooperative Oncology Group
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell LymphomaNCT00499018
Diffuse Large B...
IPI≥2
Rituximab
Ciclofosfamide
Doxorubicina
Vincristina
Prednisone
Pegfilgrastim
Mitoxantrone
ARA-C
Lenograstim
BCNU
ARA-C
VP-16
ASCT
Ciclofosfamide
Doxorubicina
Vincristina
18 Years - 60 YearsFondazione Italiana Linfomi - ETS
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaNCT02877303
B Acute Lymphob...
B Lymphoblastic...
Blinatumomab
Cyclophosphamid...
Cytarabine
Dexamethasone
Doxorubicin Hyd...
Inotuzumab Ozog...
Laboratory Biom...
Mercaptopurine
Methotrexate
Ofatumumab
Prednisone
Rituximab
Vincristine Sul...
14 Years - M.D. Anderson Cancer Center
High Dose Rituximab for Initial Treatment of Indolent B-Cell LymphomasNCT00895661
B-cell Lymphoma
Indolent B-cell...
rituximab
18 Years - Massachusetts General Hospital
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaNCT00070083
Lymphoma
oblimersen sodi...
rituximab
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
19 Years - National Cancer Institute (NCI)
Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney AllograftNCT04989491
Epstein-Barr Vi...
Rituximab
control group
18 Years - University Hospital, Strasbourg, France
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell LymphomaNCT00101010
Lymphoma
Filgrastim
Pegfilgrastim
Rituximab
Cyclophosphamid...
Pegylated lipos...
Prednisone
Vincristine Sul...
61 Years - M.D. Anderson Cancer Center
Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic LeukemiaNCT00436904
Leukemia
Alemtuzumab
Rituximab
18 Years - Mayo Clinic
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLNCT04404283
Diffuse Large B...
Brentuximab ved...
Rituximab
Lenalidomide
Placebo
18 Years - Seagen Inc.
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP OnlyNCT00451178
Lymphoma
enzastaurin
rituximab
cyclophosphamid...
doxorubicin
vincristine
prednisone
18 Years - Eli Lilly and Company
Treatment for Advanced B-Cell LymphomaNCT01859819
Diffuse Large C...
Burkitt's Lymph...
High Grade B-ce...
Rituximab
IT Cytarabine
3 Years - 31 YearsNew York Medical College
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic LeukemiaNCT00324779
Leukemia
Lymphoma
rituximab
- 18 YearsNational Cancer Institute (NCI)
Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNCT04361409
Head and Neck S...
Rituximab
Cisplatin
Gemcitabine
20 Years - 65 YearsChina Medical University Hospital
Cord Blood Natural Killer (NK) Cells in Leukemia/LymphomaNCT02280525
Leukemia
Lenalidomide
Rituximab
Fludarabine
Cyclophosphamid...
NK Cells
Cytarabine
18 Years - 80 YearsM.D. Anderson Cancer Center
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)NCT00100737
Non-Hodgkin Lym...
interleukin-2
rituximab
18 Years - Chiron Corporation
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell LymphomaNCT04002297
Mantle Cell Lym...
zanubrutinib
bendamustine
rituximab
60 Years - BeiGene
Freiburg ZNS-NHL StudyNCT00647049
Primary Non Hod...
methotrexate
Rituximab
Cytarabine
Thiotepa
Carmustin
18 Years - 65 YearsUniversity Hospital Freiburg
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaNCT00070447
Lymphoma
rituximab
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
yttrium Y 90 ib...
18 Years - National Cancer Institute (NCI)
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaNCT06047080
Large B-Cell Ly...
Glofitamab
Polatuzumab ved...
Rituximab
Cyclophosphamid...
Doxorubicin
Prednisone
18 Years - 80 YearsHoffmann-La Roche
RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis FactorNCT03536039
Lymphoma, Large...
NGR-hTNF
RITUXIMAB
Doxorubicin
Cyclophosphamid...
Vincristine
Prednisone
18 Years - 80 YearsIRCCS San Raffaele
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin LymphomaNCT01569750
CD20-positive B...
Part 1, Cohort ...
Part 1, Cohort ...
Part 1, Cohort ...
Part 2, Cohort ...
Part 2, Cohort ...
18 Years - Janssen Research & Development, LLC
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic LeukemiaNCT00759603
Chronic Lymphoc...
Small Lymphocyt...
Lenalidomide
Rituximab
18 Years - M.D. Anderson Cancer Center
Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell LymphomaNCT00689169
Lymphoma, Large...
ZBEAM (Zevalin,...
ASCT
Rituximab
18 Years - 65 YearsLymphoma Study Association
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.NCT01670370
Diffuse Large B...
R-GemOx
60 Years - The First Affiliated Hospital with Nanjing Medical University
Rituximab in Treating Patients With Hodgkin's LymphomaNCT00003820
Lymphoma
Hodgkin Lymphom...
Nodular Lymphoc...
Rituximab
3 Years - Stanford University
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's LymphomaNCT00081861
Lymphoma
Avastin
Rituximab
18 Years - M.D. Anderson Cancer Center
Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's LymphomaNCT00055640
Lymphoma
rituximab
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
microarray anal...
18 Years - Case Comprehensive Cancer Center
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaNCT02258529
Follicular Lymp...
Small Lymphocyt...
Idelalisib
Rituximab
18 Years - Gilead Sciences
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord TransplantationNCT01810588
Hematologic Mal...
CliniMACSÂŽ CD34...
Fludarabine
Melphalan
anti-thymocyte ...
Rituximab
Total Body Irra...
Mycophenolate M...
Tacrolimus
18 Years - Weill Medical College of Cornell University
Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular LymphomaNCT01493479
Follicular Lymp...
90Y Ibritumomab...
Rituximab
18 Years - The Christie NHS Foundation Trust
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell CancerNCT00546377
Leukemia
Lymphoma
filgrastim
pegfilgrastim
rituximab
sargramostim
cyclophosphamid...
mitoxantrone hy...
pentostatin
fluorescence in...
gene rearrangem...
polymerase chai...
protein express...
flow cytometry
biopsy
18 Years - 120 YearsMemorial Sloan Kettering Cancer Center
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell LymphomaNCT00144807
Diffuse Large C...
rituximab
doxorubicin
cyclophosphamid...
autologous stem...
18 Years - 59 YearsLymphoma Study Association
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.NCT00963534
Mantle Cell Lym...
lenalidomide, b...
lenalidomide, b...
65 Years - Lund University Hospital
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic LeukemiaNCT05453500
B Acute Lymphob...
Bone Marrow Asp...
Cyclophosphamid...
Doxorubicin
Etoposide
Prednisone
Rituximab
Tafasitamab
Vincristine
18 Years - University of Washington
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCLNCT01148446
Elderly Patient...
Diffuse Large B...
Cyclophosphamid...
Cyclophosphamid...
Doxorubicin
Vincristine
Prednisone
Prednisone
Epirubicin
Vinblastine
Rituximab
G-CSF
66 Years - 80 YearsFondazione Italiana Linfomi - ETS
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseNCT00176475
Leukemia
Lymphoma
Multiple Myelom...
rituximab
therapeutic all...
18 Years - Rutgers, The State University of New Jersey
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.NCT01295151
Rheumatoid Arth...
Etanercept
Abatacept
Rituximab
Adalimumab
Certolizumab Pe...
Infliximab
Golimumab
18 Years - University of Leeds
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell LymphomaNCT01776840
Mantle Cell Lym...
Bendamustine
Rituximab
Ibrutinib
Placebo
65 Years - Janssen Research & Development, LLC
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaNCT04047797
Recurrent Mantl...
Refractory Mant...
Ixazomib
Ixazomib Citrat...
Rituximab
18 Years - M.D. Anderson Cancer Center
Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)NCT00505232
Mantle Cell Lym...
Y-90 Ibritumoma...
18 Years - 70 YearsCABYC
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell LymphomaNCT00003280
Lymphoma
rituximab
18 Years - 120 YearsSwiss Group for Clinical Cancer Research
Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00193466
Non-Hodgkins Ly...
Rituximab
Fludarabine
CAMPTH-1H
18 Years - SCRI Development Innovations, LLC
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaNCT00032019
Lymphoma
filgrastim
rituximab
cyclophosphamid...
doxorubicin hyd...
etoposide
prednisone
vincristine sul...
- Alliance for Clinical Trials in Oncology
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00119392
B-cell Chronic ...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
WaldenstrĂśm Mac...
rituximab
cyclosporine
fludarabine pho...
mycophenolate m...
yttrium Y 90 ib...
peripheral bloo...
allogeneic hema...
total-body irra...
18 Years - Fred Hutchinson Cancer Center
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's LymphomaNCT00117156
Lymphoma, Non-H...
MALT Lymphoma
Fludarabine
Rituximab
18 Years - Dana-Farber Cancer Institute
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)NCT01539512
Chronic Lymphoc...
Idelalisib
Rituximab
Placebo to matc...
18 Years - Gilead Sciences
Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)NCT02316613
Follicular Lymp...
Rituximab
18 Years - Hoffmann-La Roche
Bortezomib Plus Rituximab for EBV+ PTLDNCT01058239
Post-transplant...
Solid Organ Tra...
Stem Cell Trans...
Epstein Barr Vi...
bortezomib
rituximab
18 Years - Massachusetts General Hospital
Use of Rituximab in Opsoclonus-Myoclonus in Children With NeuroblastomaNCT00202930
Neuroblastoma
Opsoclonus-myoc...
anti-CD20 (Ritu...
2 Months - 18 YearsUniversity of Pittsburgh
Lenalidomide Plus Rituxan for Untreated Mantle Cell LymphomaNCT01472562
Mantle Cell Lym...
lenalidomide
rituximab
18 Years - Weill Medical College of Cornell University
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin LymphomaNCT00863369
Lymphoma
rituximab
bortezomib
gemcitabine hyd...
questionnaire a...
18 Years - City of Hope Medical Center
Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabTheraÂŽ in Patients With Rheumatoid ArthritisNCT06175338
Rheumatoid Arth...
Rituximab
MabTheraÂŽ
18 Years - 65 YearsMabscale, LLC
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic LeukemiaNCT00769522
Chronic Lymphoc...
Rituximab
Bendamustine
Cyclophosphamid...
Fludarabine
18 Years - German CLL Study Group
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaNCT00017381
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
WaldenstrĂśm Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 YearsNational Cancer Institute (NCI)
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaNCT00275054
Chronic Lymphoc...
Fludarabine
Cyclophosphamid...
Rituximab
18 Years - German CLL Study Group
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3ANCT02406092
Non-Hodgkin Lym...
Rituximab
Cyclophosphamid...
Doxorubicin
Vincristine
Prednisone
Fludarabine
18 Years - 80 YearsHoffmann-La Roche
Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic LeukemiaNCT00436904
Leukemia
Alemtuzumab
Rituximab
18 Years - Mayo Clinic
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to TreatmentNCT00881387
Lymphoma
rituximab
gemcitabine hyd...
vinorelbine dit...
18 Years - 120 YearsUniversity of Miami
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaNCT01381692
Recurrent Folli...
Recurrent Mantl...
Recurrent Margi...
Recurrent Non-H...
Recurrent Small...
Recurrent Walde...
Refractory Foll...
Refractory Mant...
Refractory Marg...
Refractory Non-...
Refractory Smal...
Bortezomib
Dexamethasone
Laboratory Biom...
Quality-of-Life...
Rituximab
Temsirolimus
18 Years - National Cancer Institute (NCI)
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell LymphomaNCT00140660
Diffuse Large C...
rituximab
18 Years - 65 YearsLymphoma Study Association
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT01611090
Chronic Lymphoc...
Small Lymphocyt...
Ibrutinib
Bendamustine hy...
Rituximab
Placebo
18 Years - Janssen Research & Development, LLC
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic MalignanciesNCT00824135
Hematologic Mal...
Clofarabine
Stem Cell Trans...
OKT3
Thiotepa
Melphalan
Mycophenolate m...
Rituximab
G-CSF
- 21 YearsSt. Jude Children's Research Hospital
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaNCT03609593
Chronic Lymphoc...
Bendamustine
Venetoclax
Rituximab
18 Years - 99 YearsColumbia University
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaNCT04884035
Lymphoma, B-Cel...
CC-220
Rituximab
Cyclophosphamid...
Doxorubicin
Vincristine
Prednisone
CC-99282
Polatuzumab ved...
Rituximab
18 Years - Celgene
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular LymphomaNCT01902862
Lymphoma, Folli...
Bortezomib
Rituximab
18 Years - 70 YearsJanssen-Cilag G.m.b.H
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT02142049
Diffuse Large B...
Diffuse Large B...
Ibrutinib
DA-EPOCH-R
Lenalidomide
18 Years - Pharmacyclics LLC.
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaNCT00265928
Lymphoma
bortezomib
rituximab
antibody therap...
biological ther...
enzyme inhibito...
monoclonal anti...
18 Years - National Cancer Institute (NCI)
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)NCT02576275
Indolent Non-Ho...
Follicular Lymp...
Small Lymphocyt...
Marginal Zone L...
Duvelisib
Placebo
Rituximab
Bendamustine
18 Years - SecuraBio
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaNCT01594229
Non-Hodgkin's L...
ABT-199
Rituximab
Bendamustine
18 Years - 99 YearsAbbVie
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCLNCT01449344
Mantle Cell Lym...
Rituximab
High dose Ara-C
Dexamethasone
Bortezomib
18 Years - European Mantle Cell Lymphoma Network
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's LymphomaNCT00334438
Lymphoma
rituximab
bortezomib
yttrium Y 90 ib...
Indium 111 ibri...
18 Years - 120 YearsUNC Lineberger Comprehensive Cancer Center
Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCLNCT03958916
Rituximab
Lymphoma, Non-H...
Pediatric Cance...
1 Year - 18 YearsSun Yat-sen University
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)NCT04790903
Lymphoma, Large...
Venetoclax
Polatuzumab Ved...
Rituximab
Cyclophosphamid...
Doxorubicin
Prednisone
18 Years - Hoffmann-La Roche
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: